The Bid & Ask

Quotations, Dispatches, and the Daily Tape

Thursday, August 13, 2026

Subject of the day

JNJ

Concerning the House

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

United States · www.jnj.com

The Long Run

FY 2009–2025 · 17 years

LineLatestCAGRTrend
Revenue$94.19B+2.7%
Gross profit$63.94B+2.5%
Operating income$21.59B+6.8%
Net income$26.80B+19.1%
Cash from ops$22.79B+2.6%
Quotation

$262.08

+1.22 (+0.5%)

52w hi$267.24
52w lo$170.17
Vol3.33M
As ofAug 13
The Verdict

Hold

Our score +0.45

Short+0.35
Medium+0.60
Long+0.37

computed 2026-08-12

By the Numbers

Johnson & Johnson

Healthcare · Drug Manufacturers - General

Market cap$631.59B
Enterprise value$656.92B
Trailing P/E30.44x
Forward P/E21.29x
EV / EBITDA18.84x
P / S (ttm)6.45x
Profit margin21.5%
Return on equity25.7%
Revenue growth+6.6%
Earnings growth-0.9%
Debt / equity57.71
Risk Metrics
Beta vs SPX-0.03
Corr SPX-0.02
Annual vol18.8%
Annual ret+26.4%
Sharpe1.41
Max DD-15.1%

Window: 504 trading days (504 obs)

Layer Breakdown
LayerRawContribution
Fundamental+0.19
Sector+0.12
Technical+0.26
Earnings+0.00
Sentiment+0.00

macro × 1.00 · 2026-08-12

Recent Sessions
DateOpenHighLowCloseVol
Aug 13$261.73$262.58$259.65$262.083.33M
Aug 12$256.00$261.41$255.26$260.864.63M
Aug 11$261.23$264.15$258.36$259.805.95M
Aug 10$259.06$262.00$258.55$261.818.99M
Aug 7$255.89$259.60$255.12$259.246.53M